Middle East And Africa Stroke Market
市场规模（十亿美元）
CAGR :
% 
USD
1.13 Billion
USD
1.70 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 1.13 Billion |
 Market Size (Forecast Year) |
USD 1.70 Billion |
 CAGR |
% |
| Major Markets Players |
|
中東和非洲中風市場細分、類型（缺血性中風、短暫性腦缺血發作(TIA) 和出血性中風）、診斷和治療（診斷和治療）、性別（女性和男性）、最終用戶（醫院和診所、專科診所、門診手術中心、家庭護理、實驗室等）、分銷渠道（直接、零售和在線）——行業和預測到 2032 年
中風市場分析
中東和非洲中風市場是醫療保健產業中一個快速成長的領域，專注於預防、診斷、治療和復健中風患者的產品和服務。該市場的關鍵組成部分包括藥物（如血栓溶解劑、抗血小板劑和抗凝血劑）、醫療器材（如血管支架和神經保護裝置）和復健設備（包括物理治療工具和語言治療輔助器）。推動這一增長的因素包括：中風預防意識的增強、醫療技術的進步以及更容易中風的老年人口的增加。非傳染性疾病（尤其是高血壓和糖尿病）的盛行率不斷上升，進一步增加了對有效中風護理的需求。
中風市場規模
中東和非洲中風市場預計將從 2024 年的 11.3 億美元增至 2032 年的 17.0 億美元，在 2025 年至 2032 年的預測期內以 5.6% 的複合年增長率增長。除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察外，Data Bridge Market Research 策劃的市場報告還包括深度專家分析、患者流行病學、管道分析、定價分析和監管框架。
中風市場趨勢
“先進的神經影像技術和遠距醫療解決方案在中風診斷和管理中的應用日益廣泛”
中東和非洲中風市場的一個顯著趨勢是越來越多地採用先進的神經影像技術和遠距醫療解決方案來進行中風診斷和管理。隨著人們越來越意識到快速介入對中風治療的重要性，人們開始更多地使用 MRI 和 CT 掃描等複雜的影像技術，這些技術可以更快、更準確地診斷中風類型。此外，遠距醫療在提供及時諮詢和遠端監控方面變得越來越重要，特別是在農村或服務不足的地區，它使醫療專業人員能夠及時評估患者並開始治療。這一趨勢不僅改善了患者的治療效果，而且還推動了中風護理過程中的創新和投資。
報告範圍和中風市場細分
|
屬性 |
中風關鍵市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
沙烏地阿拉伯、阿聯酋、南非、埃及、以色列、科威特以及中東和非洲其他地區 |
|
主要市場參與者 |
百時美施貴寶公司（美國）、勃林格殷格翰國際有限公司（德國）、羅氏公司（瑞士）、賽諾菲（法國）、強生服務公司（美國）、拜耳公司（德國）、山德士公司（瑞士）、輝瑞公司（美國）、美敦力公司（愛爾蘭）、雅培公司（美國）、Vitanat東西（美國）、Vitanat）、Hiltaner） PHARMACEUTICALS LTD（印度）、費森尤斯公司（德國）、梯瓦製藥美國公司（以色列）及魯賓公司（印度）等 |
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深度專家分析、患者流行病學、管道分析、定價分析和監管框架。 |
中風市場定義
中東和非洲中風市場涵蓋全球中風患者預防、診斷、治療和復健所涉及的各種產品、服務和技術。這包括一系列醫療設備、藥品、影像設備和治療解決方案，旨在解決中風護理的複雜性。人口老化、生活方式因素以及對中風症狀和治療方案的認識提高導致中風發病率上升，推動了市場的發展。此外，醫療技術和遠距醫療的進步正在塑造醫療格局，促進更好的患者管理，並改善不同人口和醫療環境中的中風護理結果。
中風市場動態
驅動程式
- 中風發生率上升推動治療需求
中風發生率的上升是推動中風市場發展的重要因素，影響治療和醫療保健基礎設施的需求。中風是全球導致殘疾和死亡的主要原因，由於人口老化、久坐的生活方式、高血壓、糖尿病、吸煙和不良飲食等各種風險因素，中風變得越來越普遍。隨著預期壽命的增加和人口老化，高血壓和心房顫動等導致中風的疾病的盛行率也在上升，導致更多人患上中風並需要立即就醫和長期康復。
例如，
2023年5月，根據eClinicalMedicine發表的文章，中風將成為全球第二大死因和第三大殘疾原因。在過去 30 年中，中風發病率（70%）和盛行率（85%）的絕對數量以及中風死亡人數（43%）都有所增加。
- 高血壓、冠心病患者增多
高血壓，俗稱血壓高，是一種以血液對動脈壁的壓力升高為特徵的疾病。其典型定義是血壓讀數為 130/80 mm Hg 或更高，並且可以根據其根本原因分為必要性（原發性）或次要性。長期高血壓會導致一系列嚴重的健康問題，其中最嚴重的問題之一就是冠狀動脈心臟病。冠狀動脈心臟病，也稱為冠狀動脈疾病，是由於冠狀動脈中脂肪沉積物（動脈粥樣硬化）逐漸堆積所致，而冠狀動脈為心肌提供氧氣和營養。當這些動脈變窄或阻塞時，流向心臟的血液就會減少，導致胸痛（心絞痛），嚴重的情況下還會導致心臟病發作。
例如，
2023年9月，根據《泛美衛生組織雜誌》發表的一篇文章，高血壓通常無症狀，但卻是導致心血管疾病的重要因素，而心血管疾病是導致死亡的主要原因。老化、肥胖和不良的生活方式等因素導致盛行率上升，需要有效的治療。
機會
- 中風先進療法的開發
先進療法的開發解決了中風護理中大量未滿足的需求，為中風市場帶來了重大機會。目前的治療主要集中於透過血栓溶解或血栓切除術恢復血流，但僅在較短的時間內有效，並且無法解決潛在的神經元損傷。神經保護劑、細胞療法和標靶藥物傳遞系統等先進療法有望減輕這種損害、促進神經元修復並改善中風患者的長期功能結果。這將減少殘疾，降低與長期照護相關的醫療保健成本，並提高倖存者的生活質量，從而透過吸引投資和推動對更有效治療的需求來擴大市場潛力。
例如，
2022年4月，根據美國心臟協會期刊發表的文章，急性缺血性中風的治療持續取得進展。替奈普酶已被評估為一種替代性溶栓藥物，有證據表明其至少與阿替普酶一樣有效，並且可以更有效地溶解大血管血栓。目前已證明，對於精心挑選的近端大血管閉塞患者，採用機械血栓切除術進行血管內治療在中風發作後 24 小時內是有益的。
- 擴大中風復健服務
中風復健服務的擴展滿足了對更有效的恢復和復健計劃日益增長的需求，為中風市場提供了巨大的機會。目前，中風倖存者在恢復失去的運動和認知功能方面往往面臨重大挑戰，導致住院時間延長、醫療費用增加、生活品質下降。隨著全球人口老化和中風發病率上升，迫切需要加強復健服務，以滿足中風倖存者的個人需求。透過擴大中風復健服務，醫療保健提供者和付款人可以滿足對全面和個人化護理的未滿足需求，從而改善患者的治療效果，降低醫療保健成本，並提高患者滿意度。
例如，
2023年4月，根據MDPI發表的文章，已開發國家努力為中風患者提供復健治療。物理復健可以減少或預防中風患者已知的併發症，同時改善他們的生活品質。治療師根據損傷、活動限制和復健目標選擇介入措施。
限制/挑戰
- 診斷費用高昂
心臟病和中風是多年來全球死亡率上升的主要因素之一。中風可列為最昂貴的慢性疾病之一。每年有超過 868,000 名美國人死於心臟病或中風，佔所有死亡人數的三分之一。隨著腦中風發生率的不斷上升，診療費用逐年上漲成為限制腦中風發展的主要因素。
大多數患者不僅承受影響生計的終身殘疾，而且還帶來巨大的社會經濟影響。隨著技術進步，診斷成本也隨之增加。
例如，
根據醫療保健研究和品質機構的數據，缺血性中風的平均住院時間（包括診斷和住院）為 5.6 天，每次住院費用為 9,100 美元，出血性中風的平均住院時間為 8.4 天，每次住院費用為 19,500 美元。
- 產品召回增加
專業人員使用各種各樣的中風診斷設備對不同年齡的不同患者進行不同的治療。因此，使用這些設備所產生的副作用和併發症會對患者造成嚴重傷害。
此外，這些診斷設備和產品非常昂貴且風險極高，潛在的故障可能會對患者造成嚴重後果。因此，為了患者的安全，它們受到嚴格的監管和召回。
例如，
東軟醫療系統有限公司產品NeuViz 64多層CT掃描系統產品是一款多層CT掃描系統，用作全身電腦斷層掃描X射線系統，具有連續旋轉的X射線管和偵測器陣列，由於系統中的軟體錯誤，已被FDA召回。
本市場報告提供了最新發展、貿易法規、進出口分析、生產分析、價值鏈優化、市場份額、國內和本地化市場參與者的影響的詳細信息，分析了新興收入領域的機會、市場法規的變化、戰略市場增長分析、市場規模、類別市場增長、應用領域和主導地位、產品批准、產品發布、地理擴展、市場技術創新。要獲取更多市場信息，請聯繫 Data Bridge Market Research 獲取分析師簡報，我們的團隊將幫助您做出明智的市場決策，實現市場成長。
中風市場範圍
中風市場根據類型、診斷和治療、性別、最終用戶和分銷管道分為五個顯著的部分。這些細分市場之間的成長將幫助您分析行業中成長微弱的細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，確定核心市場應用。
類型
- 缺血性中風
- 血栓性（腦血栓）
- 栓塞（腦栓塞）
- 出血性中風
- 蜘蛛網膜下腔出血
- 腦出血
- 短暫性腦缺血發作（TIA）
診斷與治療
- 治療
- 藥物
- 按類別
- 降血壓藥
- 血管緊張素轉換酶（ACE）抑制劑
- 雷米普利
- 賴諾普利
- 依那普利
- 培哚普利
- 其他
- 噻嗪類利尿劑
- 吲達帕胺
- 芐氟噻嗪
- 螺內酯
- 阿米洛利
- 其他
- 鈣通道阻斷劑
- 氨氯地平
- 硝苯地平
- 維拉帕米
- 尼卡地平
- 非洛地平
- 尼莫地平
- 其他
- β受體阻斷劑
- 阿替洛爾
- 比索洛爾
- 拉貝洛爾
- 其他的
- 阿爾法受體阻斷劑
- 多沙唑嗪
- 其他的
- 其他的
- 血管緊張素轉換酶（ACE）抑制劑
- 抗血小板藥物
- 阿斯匹林
- 氯吡格雷
- 雙嘧達莫
- 噻氯匹定
- 其他的
- 抗凝血劑
- 華法林
- 阿哌沙班
- 達比加群
- 肝素
- 利伐沙班
- 其他
- 組織纖溶酶原激活劑（TPA）
- 阿替普酶
- 替奈普酶
- 瑞替普酶
- 阿尼普酶
- 其他
- 他汀類藥物
- 阿托伐他汀
- 辛伐他汀
- 洛伐他汀
- 瑞舒伐他汀
- 氟伐他汀
- 普伐他汀
- 匹伐他汀
- 其他的
- 維生素K
- 支持性藥物
- 營養補充品
- 退燒藥
- 其他的
- 降血壓藥
- 依藥物類型
- 品牌
- 活化酶
- 艾多巴克桑
- 華法林
- 肝素利奧
- 多普拉文
- 安格倫諾克斯
- 瑞塔瓦斯
- 詹托文
- 卡斯弗洛
- 其他
- 品牌
- 通用的
- 依給藥途徑
- 口服
- 藥片
- 膠囊
- 其他的
- 腸外
- 靜脈
- 皮下
- 其他的
- 口服
- 按購買方式
- 處方
- 場外交易（OTC）
- 按治療類型
- 合併治療
- 單藥治療
- 依給藥途徑
- 手術
- 栓塞線圈
- 抽吸導管
- 支架取栓器
- 手術夾閉
- 其他的
- 其他療法
- 物理治療
- 職能治療
- 語言治療
- 其他的
- 按類別
- 診斷
- 影像學檢查
- 電腦斷層掃描（CT）
- 磁振造影（MRI）
- 頸動脈超音波
- 腦血管攝影
- 驗血
- 超音波心臟檢查
- 腰椎穿刺
- 其他的
- 影像學檢查
- 藥物
性別
- 女性
- 男性
最終用戶
- 醫院和診所
- 專科診所
- 門診手術中心
- 居家護理
- 實驗室
- 其他的
分銷管道
- 直接的
- 零售
- 在線的
中風市場區域分析
對市場進行分析，並按類型、診斷和治療、性別、最終用戶和分銷管道提供市場規模洞察和趨勢，如上所述。
市場涵蓋的國家包括沙烏地阿拉伯、阿聯酋、南非、埃及、以色列、科威特以及中東和非洲其他地區
由於疾病負擔重、城市化以及診斷和治療管道不斷擴大，南非預計將在中風治療市場佔據主導地位。政府對非傳染性疾病的關注和私營部門的投資正在加速市場成長。
預計沙烏地阿拉伯的中風治療市場將出現強勁成長，這得益於中風發病率的上升和「2030願景」下的重大投資。關鍵因素包括醫療基礎設施的擴張、公私合作夥伴關係以及先進診斷和治療方法的普及。
報告的國家部分還提供了影響個別市場因素以及影響市場當前和未來趨勢的國內市場監管變化。下游和上游價值鏈分析、技術趨勢和波特五力分析、案例研究等數據點是用於預測各國市場情景的一些指標。此外，在對國家數據進行預測分析時，還考慮了中東和非洲品牌的存在和可用性，以及由於來自本地和國內品牌的大量或稀缺的競爭而面臨的挑戰、國內關稅和貿易路線的影響。
中風市佔率
市場競爭格局提供了競爭對手的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投資、新市場計劃、中東和非洲業務、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度、應用優勢。以上提供的數據點僅與公司對市場的關注有關。
在市場上運作的中風市場領導者是：
- 百時美施貴寶公司（美國）
- 勃林格殷格翰國際有限公司（德國）
- F. Hoffmann-La Roche Ltd（瑞士）
- 賽諾菲（法國）
- 強生服務公司（美國）
- 拜耳公司（德國）
- 山德士股份公司（瑞士）
- 輝瑞公司（美國）
- 美敦力（愛爾蘭）
- 雅培（美國）
- Viatris Inc.（美國）
- 阿斯特捷利康（英國）
- Penumbra, Inc.（美國）
- 格蘭馬克製藥有限公司（印度）
- Fresenius SE & Co. KGaA（德國）
- Teva Pharmaceuticals USA, Inc.（以色列）
- 魯冰花（印度）
中風市場的最新發展
- 2023 年 7 月，羅氏宣布與 Alnylam 建立新的合作夥伴關係，以開發和商業化 zilebesir，這是一種目前處於 2 期治療高血壓的試驗性 RNAi 療法。此次合作將 Alnylam 在 RNAi 治療領域的成熟經驗與羅氏的全球商業影響力、創新承諾以及改變嚴重心血管疾病患者治療格局的願望相結合
- 2020年9月，第一三共株式會社宣布已在日本提交補充申請，要求延長抗凝血藥艾多沙班（苯甲酸艾多沙班水合物）用於治療非瓣膜逆流和嚴重出血的老年患者。風險。該申請基於日本一項 3 期臨床試驗（ELDERCARE-AF 試驗）的結果，該試驗對 984 名年齡至少 80 歲、出血風險高且不適合其他可用抗凝血療法的非瓣膜性心房顫動患者進行了研究。第一三共計劃透過提供新的治療選擇，為老年非瓣膜性心房顫動患者的治療做出貢獻
- 2022年7月，全球領先的仿製藥和生物類似藥製造商山德士宣布向其位於斯洛維尼亞盧布爾雅那的工廠投資約9,000萬美元，計劃在2026年建立山德士生物製藥開發中心。透過這項投資，盧布爾雅那工廠將成為山德士最重要的生物相似藥產品開發基地之一。新辦公室將創造約 200 個新的全職工作崗位，並將進一步增強公司在生物相似藥和醫藥產品開發方面的能力
- 2023年1月，專注於創新療法的醫療保健公司Penumbra, Inc.宣布美國食品藥物管理局（FDA）批准並推出市場上最先進、最強大的機械血栓切除系統Lightning Flash™。 Lightning Flash 採用 Penumbra 全新的 Lightning Intelligent Aspiration 技術，目前擁有兩種血塊偵測演算法。 Lightning Flash 結合創新導管技術，旨在快速清除體內的大血栓，包括靜脈栓塞和肺栓塞 (PE)。此次發布將有助於該公司擴大其產品組合，因為這項新技術的先進成果具有極強的可追溯性，並且具有區分流動血液和血塊的獨特能力
- 2023 年 8 月，魯賓宣布推出致力於心臟健康的病患支援計畫 Jeet。該計劃的啟動恰逢印度第77個獨立日，象徵人們擺脫疾病帶來的壓力，走向更幸福、更健康的生活。 Jeet 透過提供成本節約、醫療援助、藥物提醒和生活方式支持等各種福利，成為心血管護理領域值得信賴的合作夥伴。 Jeet 透過提高人們對心血管疾病及其合併症的認識，提供了一種整體方法來改善醫生和患者的體驗。該應用程式包含旨在鼓勵更健康的生活方式和支持心臟健康的功能。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 LIMITATIONS
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 MIDDLE EAST AND AFRICA STROKE MARKET, REGULATORY FRAMEWORK
5.1 REGULATION IN U.S.
5.2 REGULATION IN EUROPE
5.3 REGULATION IN CHINA
5.4 REGULATION IN JAPAN
5.5 REGULATION IN SOUTH AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS
6.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES
6.1.3 INCREASING DIABETIC AND OBESE POPULATIONS ELEVATE STROKE RISKS
6.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY IMPROVE STROKE CARE OUTCO.MES
6.2 RESTRAINTS
6.2.1 HIGH COST OF DIAGNOSIS
6.2.2 INCREASE IN PRODUCT RECALL
6.3 OPPORTUNITIES
6.3.1 DEVELOPMENT OF ADVANCED THERAPEUTICS FOR STROKES
6.3.2 EXPANSION IN STROKE REHABILITATION SERVICES
6.3.3 INNOVATIVE TREATMENTS IN PIPELINE FOR STROKE TREATMENT
6.4 CHALLENGES
6.4.1 FALSE DIAGNOSIS IN STROKES
6.4.2 COMPLICATIONS ASSOCIATED WITH MANAGING STROKE
7 MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE
7.1 OVERVIEW
7.2 ISCHEMIC STROKE
7.2.1 THROMBOTIC (CEREBRAL THROMBOSIS)
7.2.2 EMBOLIC (CEREBRAL EMBOLISM)
7.3 HEMORRHAGIC STROKE
7.3.1 SUBARACHNOID HEMORRHAGE
7.3.2 INTRACEREBRAL HEMORRHAGE
7.4 TRANSIENT ISCHEMIC ATTACT (TIA)
8 MIDDLE EAST AND AFRICA STROKE MARKET, BY GENDER
8.1 OVERVIEW
8.2 FEMALE
8.3 MALE
9 MIDDLE EAST AND AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT
9.1 OVERVIEW
9.2 TREATMENT
9.2.1 BY TREATMENT TYPE
9.2.1.1 MEDICATION
9.2.1.1.1 MEDICATION, BY CLASS
9.2.1.1.1.1 BLOOD PRESSURE MEDICINES
9.2.1.1.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
9.2.1.1.1.1.2 RAMIPRIL
9.2.1.1.1.1.3 LISINOPRIL
9.2.1.1.1.1.4 ENALAPRIL
9.2.1.1.1.1.5 PERINDOPRIL
9.2.1.1.1.1.6 OTHER
9.2.1.1.1.2 THIAZIDE DIURETICS
9.2.1.1.1.2.1 INDAPAMIDE
9.2.1.1.1.2.2 BENDROFLUMETHIAZIDE
9.2.1.1.1.2.3 SPIRONOLACTONE
9.2.1.1.1.2.4 AMILORIDE
9.2.1.1.1.2.5 OTHER
9.2.1.1.1.3 CALCIUM CHANNEL BLOCKERS
9.2.1.1.1.3.1 AMLODIPINE
9.2.1.1.1.3.2 NIFEDIPINE
9.2.1.1.1.3.3 VERAPAMIL
9.2.1.1.1.3.4 NICARDIPINE
9.2.1.1.1.3.5 FELODIPINE
9.2.1.1.1.3.6 NIMODIPINE
9.2.1.1.1.3.7 OTHERS
9.2.1.1.1.4 BETA BLOCKERS
9.2.1.1.1.4.1 ATENOLOL
9.2.1.1.1.4.2 BISOPROLOL
9.2.1.1.1.4.3 LABETOLOL
9.2.1.1.1.4.4 OTHERS
9.2.1.1.1.5 ALPHA-BLOCKERS
9.2.1.1.1.5.1 DOXAZOSIN
9.2.1.1.1.5.2 OTHERS
9.2.1.1.1.6 OTHERS
9.2.1.1.1.7 ANTIPLATELET DRUGS
9.2.1.1.1.7.1 ASPIRIN
9.2.1.1.1.7.2 CLOPIDOGREL
9.2.1.1.1.7.3 DIPYRIDAMOLE
9.2.1.1.1.7.4 TICLOPIDINE
9.2.1.1.1.7.5 OTHERS
9.2.1.1.1.8 ANTICOAGULANTS
9.2.1.1.1.8.1 WARFARIN
9.2.1.1.1.8.2 APIXABAN
9.2.1.1.1.8.3 DABIGATRAN
9.2.1.1.1.8.4 HEPARIN
9.2.1.1.1.8.5 RIVAROXABAN
9.2.1.1.1.8.6 OTHERS
9.2.1.1.1.9 TISSUE PLASMINOGEN ACTIVATOR (TPA)
9.2.1.1.1.9.1 ALTEPLASE
9.2.1.1.1.9.2 TENECTEPLASE
9.2.1.1.1.9.3 RETEPLASE
9.2.1.1.1.9.4 ANISTREPLASE
9.2.1.1.1.9.5 OTHERS
9.2.1.1.1.10 STATINS
9.2.1.1.1.10.1.1 ATORVASTATIN
9.2.1.1.1.10.1.2 SIMVASTATIN
9.2.1.1.1.10.1.3 LOVASTATIN
9.2.1.1.1.10.1.4 ROSUVASTATIN
9.2.1.1.1.10.1.5 FLUVASTATIN
9.2.1.1.1.10.1.6 PRAVASTATIN
9.2.1.1.1.10.1.7 PITAVASTATIN
9.2.1.1.1.10.1.8 OTHERS
9.2.1.1.1.11 VITAMIN K
9.2.1.1.1.12 SUPPORTIVE MEDICATION
9.2.1.1.1.12.1 NUTRITIONAL SUPPLEMENTS
9.2.1.1.1.12.2 ANTIPYRETICS
9.2.1.1.1.12.3 OTHERS
9.2.1.1.2 MEDICATION, BY DRUG TYPE
9.2.1.1.2.1 BRANDED
9.2.1.1.2.1.1 ACTIVASE
9.2.1.1.2.1.2 EDOBAXAN
9.2.1.1.2.1.3 COUMADIN
9.2.1.1.2.1.4 HEPARIN LEO
9.2.1.1.2.1.5 DUOPLAVIN
9.2.1.1.2.1.6 AGGRENOX
9.2.1.1.2.1.7 RETAVASE
9.2.1.1.2.1.8 JANTOVEN
9.2.1.1.2.1.9 CATHFLO
9.2.1.1.2.1.10 OTHER
9.2.1.1.2.2 GENERIC
9.2.1.1.3 MEDICATION, BY ROUTE OF ADMINISTRATION
9.2.1.1.3.1 ORAL
9.2.1.1.3.1.1 TABLET
9.2.1.1.3.1.2 CAPSULES
9.2.1.1.3.1.3 OTHERS
9.2.1.1.3.2 PARENTERAL
9.2.1.1.3.2.1 INTRAVENOUS
9.2.1.1.3.2.2 SUBCUTANEOUS
9.2.1.1.3.3 OTHERS
9.2.1.1.4 MEDICATION, BY MODE OF PURCHASE
9.2.1.1.4.1 PRESCRIPTION
9.2.1.1.4.2 OVER THE COUNTER (OTC)
9.2.1.1.5 MEDICATION, BY THERAPY TYPE
9.2.1.1.5.1 COMBINATION THERAPY
9.2.1.1.5.2 MONOTHERAPY
9.2.1.2 SURGERY
9.2.1.2.1 EMBOLIC COILS
9.2.1.2.2 ASPIRATION CATHETERS
9.2.1.2.3 STENT RETRIEVER
9.2.1.2.4 SURGICAL CLIPPING
9.2.1.2.5 OTHERS
9.2.1.3 OTHERS THERAPY
9.2.1.3.1 PHYSICAL THERAPY
9.2.1.3.2 OCCUPATIONAL THERAPY
9.2.1.3.3 SPEECH THERAPY
9.2.1.3.4 OTHERS
9.3 DIAGNOSIS
9.3.1 IMAGING TEST
9.3.1.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN
9.3.1.2 MAGNETIC RESONANCE IMAGING (MRI)
9.3.1.3 CAROTID ULTRASOUND
9.3.1.4 CEREBRAL ANGIOGRAM
9.3.2 BLOOD TEST
9.3.3 ECHOCARDIOGRAM
9.3.4 LUMBAR PUNCTURE
9.3.5 OTHERS
10 MIDDLE EAST AND AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT
10.3 RETAIL
10.4 ONLINE
11 MIDDLE EAST AND AFRICA STROKE MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS & CLINICS
11.3 SPECIALTY CLINICS
11.4 AMBULATORY SURGICAL CENTER
11.5 HOMECARE
11.6 LABORATORIES
11.7 OTHERS
12 MIDDLE EAST AND AFRICA STROKE MARKET, BY REGION
12.1 MIDDLE EAST AND AFRICA
12.1.1 SOUTH AFRICA
12.1.2 SAUDI ARABIA
12.1.3 EGYPT
12.1.4 U.A.E.
12.1.5 ISRAEL
12.1.6 KUWAIT
13 MIDDLE EAST AND AFRICA STROKE MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 BRISTOL-MYERS SQUIBB COMPANY
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.2 F. HOFFMANN-LA ROCHE LTD
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 DAIICHI SANKYO COMPANY, LIMITED
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 SANOFI
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AMNEAL PHARMACEUTICALS LLC
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ASTRAZENECA
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BAYER AG
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 FRESENIUS SE & CO. KGAA
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 GLENMARK PHARMACEUTICALS LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 JOHNSON & JOHNSON SERVICES, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LUPIN
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.14 MEDTRONIC
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 PENUMBRA, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 PFIZER INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 SANDOZ AG
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 TEVA PHARMACEUTICALS USA, INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENT
15.19 VIATRIS INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 MIDDLE EAST AND AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACT (TIA) IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA FEMALE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA MALE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA TREATMENT IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA BLOOD PRESSURE MEDICINES IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA DIAGNOSIS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA DIRECT IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA HOSPITALS & CLINICS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTER IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA HOMECARE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA LABORATORIES IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA OTHERS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA STROKE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 MIDDLE EAST AND AFRICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 78 MIDDLE EAST AND AFRICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 79 MIDDLE EAST AND AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 80 SOUTH AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 SOUTH AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 SOUTH AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 SOUTH AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 84 SOUTH AFRICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 86 SOUTH AFRICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 87 SOUTH AFRICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 88 SOUTH AFRICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 89 SOUTH AFRICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 90 SOUTH AFRICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 91 SOUTH AFRICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 92 SOUTH AFRICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 93 SOUTH AFRICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 94 SOUTH AFRICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 95 SOUTH AFRICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 96 SOUTH AFRICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 97 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 SOUTH AFRICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 100 SOUTH AFRICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 SOUTH AFRICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 103 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 SOUTH AFRICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 SOUTH AFRICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 SOUTH AFRICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 SOUTH AFRICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 SOUTH AFRICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 109 SOUTH AFRICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 110 SOUTH AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 111 SAUDI ARABIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 SAUDI ARABIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 SAUDI ARABIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 SAUDI ARABIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 115 SAUDI ARABIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 117 SAUDI ARABIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 118 SAUDI ARABIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 119 SAUDI ARABIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 120 SAUDI ARABIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 121 SAUDI ARABIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 122 SAUDI ARABIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 123 SAUDI ARABIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 124 SAUDI ARABIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 125 SAUDI ARABIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 126 SAUDI ARABIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 127 SAUDI ARABIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 128 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 SAUDI ARABIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 131 SAUDI ARABIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 SAUDI ARABIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 134 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 SAUDI ARABIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 SAUDI ARABIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 SAUDI ARABIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 SAUDI ARABIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 SAUDI ARABIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 140 SAUDI ARABIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 141 SAUDI ARABIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 142 EGYPT STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 EGYPT ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 EGYPT HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 EGYPT STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 146 EGYPT TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 EGYPT MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 148 EGYPT BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 149 EGYPT ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 150 EGYPT THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 151 EGYPT CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 152 EGYPT BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 153 EGYPT ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 154 EGYPT ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 155 EGYPT ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 156 EGYPT TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 157 EGYPT STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 158 EGYPT SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 159 EGYPT MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 EGYPT BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 EGYPT MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 162 EGYPT ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 EGYPT PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 EGYPT MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 165 EGYPT MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 EGYPT SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 EGYPT OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 EGYPT DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 EGYPT IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 EGYPT STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 171 EGYPT STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 172 EGYPT STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 173 U.A.E. STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 174 U.A.E. ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 U.A.E. HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 U.A.E. STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 177 U.A.E. TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 U.A.E. MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 179 U.A.E. BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 180 U.A.E. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 181 U.A.E. THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 182 U.A.E. CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 183 U.A.E. BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 184 U.A.E. ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 185 U.A.E. ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 186 U.A.E. ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 187 U.A.E. TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 188 U.A.E. STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 189 U.A.E. SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 190 U.A.E. MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 U.A.E. BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 U.A.E. MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 193 U.A.E. ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 U.A.E. PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 U.A.E. MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 196 U.A.E. MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 U.A.E. SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 U.A.E. OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 U.A.E. DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 U.A.E. IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 U.A.E. STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 202 U.A.E. STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 203 U.A.E. STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 204 ISRAEL STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 ISRAEL ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 ISRAEL HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 ISRAEL STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 208 ISRAEL TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 ISRAEL MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 210 ISRAEL BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 211 ISRAEL ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 212 ISRAEL THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 213 ISRAEL CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 214 ISRAEL BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 215 ISRAEL ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 216 ISRAEL ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 217 ISRAEL ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 218 ISRAEL TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 219 ISRAEL STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 220 ISRAEL SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 221 ISRAEL MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 ISRAEL BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 ISRAEL MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 224 ISRAEL ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 ISRAEL PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 ISRAEL MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 227 ISRAEL MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 ISRAEL SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 ISRAEL OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 ISRAEL DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 ISRAEL IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 ISRAEL STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 233 ISRAEL STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 234 ISRAEL STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 235 KUWAIT STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 236 KUWAIT ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 KUWAIT HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 KUWAIT STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 239 KUWAIT TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 KUWAIT MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 241 KUWAIT BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 242 KUWAIT ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 243 KUWAIT THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 244 KUWAIT CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 245 KUWAIT BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 246 KUWAIT ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 247 KUWAIT ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 248 KUWAIT ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 249 KUWAIT TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 250 KUWAIT STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 251 KUWAIT SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 252 KUWAIT MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 KUWAIT BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 KUWAIT MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 255 KUWAIT ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 KUWAIT PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 KUWAIT MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 258 KUWAIT MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 KUWAIT SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 KUWAIT OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 KUWAIT DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 KUWAIT IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 KUWAIT STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 264 KUWAIT STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 265 KUWAIT STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 266 REST OF MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA STROKE MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA STROKE MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA STROKE MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA STROKE MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA STROKE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA STROKE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA STROKE MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA STROKE MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA STROKE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA STROKE MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA STROKE MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 12 ISCHEMIC STROKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA STROKE MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 13 MIDDLE EAST AND AFRICA STROKE MARKET EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA STROKE MARKET
FIGURE 16 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, 2024
FIGURE 17 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 18 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 19 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, 2024
FIGURE 21 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, 2025 TO 2032 (USD THOUSAND)
FIGURE 22 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, CAGR (2025- 2032)
FIGURE 23 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, 2024
FIGURE 25 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 26 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2025-2032)
FIGURE 27 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 29 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
FIGURE 30 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 31 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, 2024
FIGURE 33 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 34 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, CAGR (2025-2032)
FIGURE 35 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA STROKE MARKET: SNAPSHOT (2024)
FIGURE 37 MIDDLE EAST AND AFRICA STROKE MARKET: COMPANY SHARE 2024 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
